Dr. Park is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
260 Danny Thomas Place
Memphis, TN 38105Phone+1 901-595-4329
Education & Training
- University of WashingtonFellowship, Pediatric Hematology/Oncology, 1991 - 1994
- University of WashingtonResidency, Pediatrics, 1988 - 1991
- University of Vermont College of MedicineClass of 1988
Certifications & Licensure
- TN State Medical License 2023 - 2025
- WA State Medical License 1988 - 2023
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2014
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
Clinical Trials
- N99-02: Melphalan and Buthionine Sulfoximine Start of enrollment: 2001 Aug 01
- Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma Start of enrollment: 2000 May 01
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsOutcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology...Julie Voeller, Howard M Katzenstein, Arlene Naranjo, Sheena C Tenney, Lulu Chen
Pediatric Blood & Cancer. 2025-01-01 - 1 citationsSTRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.Navin Pinto, Catherine M Albert, Mallory R Taylor, Heidi B Ullom, Ashley L Wilson
Journal of Clinical Oncology. 2024-12-10 - CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials.Rebecca Ronsley, Kelsey C Bertrand, Edward Z Song, Andrea Timpanaro, Michelle Choe
Cancer Metastasis Reviews. 2024-12-01
Abstracts/Posters
- Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In VivoJulie R. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable ResponsesJulie R. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- FDA Committee Unanimously Rejects 131-I-Omburtamab for NeuroblastomaOctober 28th, 2022
- Practice-Changing Trial in Neuroblastoma, but Questions RemainAugust 27th, 2019
- 74 Oncologists on the MoveOctober 11th, 2023
Grant Support
- COG Advl0419: Valproic Acid In Children With Recurrent/Progressive Solid TumorsNational Center For Research Resources2007
- COG Advl0416: A Phase 1 Study Of SAHA In Pediatric Patients With RecurrentNational Center For Research Resources2007
- COG Advl0413: A Phase I Study Of The RAF Kinase And Receptor Tyrosine KinaseNational Center For Research Resources2007
- NANT 2004-01: A Phase I Study Of Zoledronic Acid (ZOMETA) With CyclophosphamideNational Center For Research Resources2006–2007
- NANT 2003-01: A Phase I Study Of Oral Irinotecan, Temozolomide, And CefiximeNational Center For Research Resources2006–2007
- Advl0319 Phase I Study Of CC-5013 (LENALIDOMIDE) In Pediatric PatientsNational Center For Research Resources2006–2007
- NANT 2001-03: Phase 1 Study Of CEP-701 In Patients With Refractory NeuroblastomaNational Center For Research Resources2004–2007
- COG Advl0416: A Study Of SAHA In Pediatric Patients Wth Recurrent Solid TumorsNational Center For Research Resources2006
- COG Advl0317: A Phase I Study Of PS-341 (Velcade, Bortezomiv) In Ped PatientsNational Center For Research Resources2006
- COG Advl0316: A Phase I Study Of 17-AAG In Relapsed/Refractory PediatricNational Center For Research Resources2006
- COG Advl0214: A Phase I Study Of Single Agent OSI-774 (TARCEVA)National Center For Research Resources2006
- COG Advl0314: A Phase 1 Study Of Bevacizumab In Refractory Solid TumorsNational Center For Research Resources2005–2006
- NANT 2002-01 Phase 1 Study Of High Dose Pyrasolacridine (Pza)(Nsc 366140) SupporNational Center For Research Resources2004–2006
- Novel Therapies For High-Risk NeuroblastomaNational Cancer Institute2002–2006
- Cog-Anbl02p1: A Pilot Induction Regimen Incorporating Topotecan For Treatment ONational Center For Research Resources2005
- Cog-Advl0311: Pemetrexed In Children And Adolescents With Recurrent Solid TumorsNational Center For Research Resources2005
- COG Advl0316: 17-AAG In Pediatric Patients With Solid Tumors Or LeukemiaNational Center For Research Resources2005
- COG Advl0215: Decitabine In Combination With Doxorubicin And CyclophosphamideNational Center For Research Resources2005
- COG Advl0211: G3139 With Cytotoxic Chemotherapy In Relapsed Childhood TumorsNational Center For Research Resources2005
- Cog-Anbl0321: A Phase II Study Of Fenretinide (Nsc #374551, IND #40294) In ChiaNational Center For Research Resources2004
- COG Advl0215: A Phase I Study Of Decitabine (Nsc #127716, IND #50733) In CombinNational Center For Research Resources2004
- COG Advl0212 - A Phase I Study Of Depsipeptide (Nsc # 630176, IND # 51810) In PSNational Center For Research Resources2004
- COG Advl0211 - A Phase I Trial Of G3139 (Bcl-2 Antisense, NSC# 683428, Ind# 588sNational Center For Research Resources2004
- Ccg-A0981, A Phase I Intergroup Trial Of The Hu14.18-Il2 Fusion Protein In ChilsNational Center For Research Resources2004
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: